The present study investigated the association between patient characteristics, including metastatic sites and the efficacy of erlotinib treatment in EGFR-mutation negative NSCLC, and demonstrated that pulmonary metastasis was a significant and independent factor associated with PFS and OS. Here, EGFR is linked to non-small cell lung carcinoma.